rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2021-12-05rpcardio-2623Research ArticleORIGINAL STUDIESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯPatients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and OutcomesБольные с сочетанием фибрилляции предсердий и хронической сердечной недостаточности в клинической практике: сопутствующие заболевания, медикаментозное лечение и исходыhttps://orcid.org/0000-0002-5784-4525ЛукьяновМ. М.LoukianovM. M.
https://orcid.org/0000-0003-2659-820XПоздняковаЕ. М.PozdnyakovaE. M.
Позднякова Екатерина Михайловна.
Ярославль.
Ekaterina M. Pozdnyakova.
Yaroslavl.
https://orcid.org/0000-0002-5588-9316ГомоваТ. А.GomovaT. A.
Гомова Татьяна Александровна.
Тула.
Tatiana A. Gomova.
Tula.
https://orcid.org/0000-0003-1071-1837ФедотоваЕ. Е.FedotovaE. E.
Федотова Елена Евгеньевна.
Тула.
Elena E. Fedotova.
Tula.
https://orcid.org/0000-0002-2916-4047ВалиахметовМ. Н.ValiakhmetovM. N.
Валиахметов Марат Нафизович.
Тула.
Marat N. Valiakhmetov.
Tula.
https://orcid.org/0000-0002-5398-9727МихинВ. П.MikhinV. P.
Михин Вадим Петрович.
Курск.
Vadim P. Mikhin.
Kursk.
https://orcid.org/0000-0002-1877-1992МасленниковаЮ. В.MaslennikovaYu. V.
Масленникова Юлия Вениаминовна.
Курск.
Yulia V. Maslennikova.
Kursk.
https://orcid.org/0000-0002-8169-8919БеловаЕ. Н.BelovaE. N.
Белова Екатерина Николаевна.
Москва.
Ekaterina N. Belova.
Moscow.
https://orcid.org/0000-0002-5501-5731КляшторныйВ. Г.KlyashtornyV. G.
Кляшторный Владислав Георгиевич.
Москва.
Vladislav G. Klyashtorny.
Moscow.
https://orcid.org/0000-0002-2361-7172КудряшовЕ. В.KudryashovE. V.
Кудряшов Егор Николаевич.
Москва.
Egor V. Kudryashov.
Moscow.
https://orcid.org/0000-0002-9111-8738МаковееваА. Н.MakoveevaA. N.
Маковеева Анна Николаевна.
Москва.
Anna N. Makoveeva.
Moscow.
https://orcid.org/0000-0002-5150-5952ТацийЮ. Е.TatsiyYu. E.
Таций Юлия Евгеньевна.
Москва.
Julia E. Tatsii.
Moscow.
https://orcid.org/0000-0001-6998-8406БойцовС. А.BoytsovS. A.
Бойцов Сергей Анатольевич.
Москва.
Sergey A. Boytsov.
Moscow.
https://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.
Драпкина Оксана Михайловна.
Москва.
Oksana M. Drapkina.
Moscow.
Национальный медицинский исследовательский центр Терапии и профилактической медициныРоссияNational Medical Research Center for Therapy and Preventive MedicineRussian FederationРязанский государственный медицинский университет им. академика И.П. ПавловаРоссияRyazan State Medical University named after Academician I.P. PavlovRussian FederationЯрославский государственный медицинский университетРоссияYaroslavl State Medical UniversityRussian FederationТульская областная клиническая больницаРоссияTula Regional Clinical HospitalRussian FederationГородская больница №3РоссияTula City hospital №3Russian FederationКурский государственный медицинский университетРоссияKursk State Medical UniversityRussian FederationНациональный медицинский исследовательский центр кардиологииРоссияNational Medical Research Center of CardiologyRussian Federation202112012022176816824Copyright © Loukianov M.M., Martsevich S.Y., Mareev Y.V., Yakushin S.S., Andreenko E.Y., Vorobiev A.N., Pereverzeva K.G., Zagrebelny A.V., Okshina E.Y., Yakusevich V.V., Yakusevich V.V., Pozdnyakova E.M., Gomova T.A., Fedotova E.E., Valiakhmetov M.N., Mikhin V.P., Maslennikova Y.V., Belova E.N., Klyashtorny V.G., Kudryashov E.V., Makoveeva A.N., Tatsiy Y.E., Boytsov S.A., Drapkina O.M., 20222022Лукьянов М.М., Марцевич С.Ю., Мареев Ю.В., Якушин С.С., Андреенко Е.Ю., Воробьев А.Н., Переверзева К.Г., Загребельный А.В., Окшина Е.Ю., Якусевич В.В., Якусевич В.В., Позднякова Е.М., Гомова Т.А., Федотова Е.Е., Валиахметов М.Н., Михин В.П., Масленникова Ю.В., Белова Е.Н., Кляшторный В.Г., Кудряшов Е.В., Маковеева А.Н., Таций Ю.Е., Бойцов С.А., Драпкина О.М.Loukianov M.M., Martsevich S.Y., Mareev Y.V., Yakushin S.S., Andreenko E.Y., Vorobiev A.N., Pereverzeva K.G., Zagrebelny A.V., Okshina E.Y., Yakusevich V.V., Yakusevich V.V., Pozdnyakova E.M., Gomova T.A., Fedotova E.E., Valiakhmetov M.N., Mikhin V.P., Maslennikova Y.V., Belova E.N., Klyashtorny V.G., Kudryashov E.V., Makoveeva A.N., Tatsiy Y.E., Boytsov S.A., Drapkina O.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/2623Aim
Aim. To assess in clinical practice the structure of multimorbidity, cardiovascular pharmacotherapy and outcomes in patients with a combination of atrial fibrillation (AF) and chronic heart failure (CHF) based on prospective registries of patients with cardiovascular diseases (CVD).
Materials and Methods
Materials and Methods. The data of 3795 patients with atrial fibrillation (AF) were analyzed within the registries RECVASA (Ryazan), RECVASA FP (Moscow, Kursk, Tula, Yaroslavl), REGION-PO and REGION-LD (Ryazan), REGION-Moscow, REGATA (Ryazan). The comparison groups consisted of 3016 (79.5%) patients with AF in combination with CHF and 779 (29.5%) patients with AF without CHF. The duration of prospective observation is from 2 to 6 years.
Results
Results. Patients with a combination of AF and CHF (n=3016, age was 72.0±10.3 years; 41.8% of men) compared with patients with AF without CHF (n=779, age was 70.3±12.0 years; 43.5% of men) had a higher risk of thromboembolic complications (CHA2DS2-VASc – 4.68±1.59 and 3.10±1.50; p<0.001) and hemorrhagic complications (HAS-BLED – 1.59±0.77 and 1.33±0.76; p<0.05). Patients with a combination of AF and CHF significantly more often (p<0.001) than in the absence of CHF were diagnosed with arterial hypertension (93.9% and 83.8%), coronary heart disease (87.9% and 53,5%), myocardial infarction (28.4% and 14.0%), diabetes mellitus (22.4% and 7.7%), chronic kidney disease (24.8% and 16.2%), as well as respiratory diseases (20.1% and 15.3%; p=0.002). Patients with AF in the presence of CHF, compared with patients without CHF, were more often diagnosed with a permanent form of arrhythmia (49.3% and 32.9%; p<0.001) and less often paroxysmal (22.5% and 46.2%; p<0.001) form of arrhythmia. Ejection fraction ≤40% (9.3% and 1.2%; p<0.001), heart rate ≥90/min (23.7% and 19.3%; p=0.008) and blood pressure ≥140/90 mm Hg (59.9% and 52.2%; p<0.001) were recorded with AF in the presence of CHF more often than in the absence of CHF. The frequency of proper cardiovascular pharmacotherapy was higher, albeit insufficient, in the presence of CHF (64.9%) than in the absence of it (56.1%), but anticoagulants were prescribed less frequently when AF and CHF were combined (38.8% and 49, 0%; p<0.001). The frequency of unreasonable prescription of antiplatelet agents instead of anticoagulants was 52.5% and 33.3% (p<0.001) in the combination of AF, CHF and coronary heart disease, as well as in the combination of AF with coronary heart disease but without CHF. Patients with AF and CHF during the observation period compared with those without CHF had higher mortality from all causes (37.6% and 30.3%; p=0.001), the frequency of non-fatal cerebral stroke (8.2% and 5.4%; p=0.032) and myocardial infarction (4.7% and 2.5%; p=0.036), hospitalizations for CVD (22.8% and 15.5%; p<0.001).
Conclusion
Conclusion. Patients with a combination of AF and CHF, compared with the group of patients with AF without CHF, were older, had a higher risk of thromboembolic and hemorrhagic complications, they were more often diagnosed with other concomitant cardiovascular and chronic noncardiac diseases, decreased left ventricular ejection fraction, tachysystole, failure to achieve the target blood pressure level in the presence of arterial hypertension. The frequency of prescribing proper cardiovascular pharmacotherapy was higher, albeit insufficient, in the presence of CHF, while the frequency of prescribing anticoagulants was less. The incidence of mortality from all causes, the development of non-fatal myocardial infarction and cerebral stroke, as well as the incidence of hospitalizations for CVDs were higher in AF associated with CHF.
Цель
Цель. Оценить структуру мультиморбидности, кардиоваскулярную фармакотерапию и исходы у больных с сочетанием фибрилляции предсердий (ФП) и хронической сердечной недостаточности (ХСН) в клинической практике в рамках проспективных регистров больных сердечно-сосудистыми заболеваниями (ССЗ).
Материал и методы
Материал и методы. В рамках регистров РЕКВАЗА (Рязань), РЕКВАЗА ФП (Москва, Курск, Тула, Ярославль), РЕГИОН-ПО и РЕГИОН-ЛД (Рязань), РЕГИОН-Москва, РЕГАТА (Рязань) проанализированы данные 3795 пациентов с фибрилляцией предсердий (ФП). Группы сравнения составили 3016 (79,5%) пациентов с ФП в сочетании с ХСН и 779 (29,5%) – с ФП без ХСН. Длительность проспективного наблюдения – от 2 до 6 лет.
Результаты
Результаты. У больных с сочетанием ФП и ХСН (n=3016, возраст 72,0±10,3 лет; 41,8% мужчин) по сравнению с пациентами с ФП без ХСН (n=779, возраст 70,3±12,0 лет; 43,5% мужчин) был выше риск тромбоэмболических осложнений (CHA2DS2-VASc – 4,68±1,59 и 3,10±1,50; p<0,001) и геморрагических осложнений (HAS-BLED – 1,59±0,77 и 1,33±0,76; p<0,05). У больных с сочетанием ФП и ХСН значимо чаще (p<0,0001), чем при отсутствии ХСН диагностировались артериальная гипертония (93,9% и 83,8%), ишемическая болезнь сердца (ИБС; 87,9% и 53,5%), перенесенный инфаркт миокарда (28,4% и 14,0%), сахарный диабет (22,4% и 7,7%), хроническая болезнь почек (24,8% и 16,2%), а также болезни органов дыхания (20,1% и 15,3%; р=0,002). У больных с ФП на фоне ХСН по сравнению с пациентами без ХСН чаще диагностировались постоянная (49,3% и 32,9%; р<0,0001) и реже – пароксизмальная (22,5% и 46,2%; р<0,0001) формы аритмии. При ФП на фоне ХСН чаще, чем при отсутствии ХСН регистрировались фракция выброса ≤40% (9,3% и 1,2%; р<0,0001), ЧСС≥90/мин (23,7% и 19,3%; р=0,008) и АД 140/90 мм рт.ст. (59,9% и 52,2%; р<0,0001). Частота должной кардиоваскулярной фармакотерапии была более высокой, хотя и недостаточной, при наличии ХСН (64,9%), чем при ее отсутствии (56,1%), однако, антикоагулянты назначались реже при сочетании ФП и ХСН (38,8% и 49,0%; p<0,0001). При сочетании ФП, ХСН и ИБС, а также при сочетании ФП с ИБС, но без ХСН частота необоснованного назначения антиагрегантов вместо антикоагулянтов составила 52,5% и 33,3% (p<0,0001), У больных с ФП и ХСН за период наблюдения были выше, чем у лиц без ХСН смертность от всех причин (37,6% и 30,3%; р=0,001), частота нефатальных мозгового инсульта (8,2% и 5,4%; р=0,032) и инфаркта миокарда (4,7% и 2,5%; р=0,036), госпитализаций по поводу ССЗ (22,8% и 15,5%; р<0,0001).
Заключение
Заключение. У больных с сочетанием ФП и ХСН по сравнению с группой пациентов с ФП без ХСН были старше возраст, выше риски тромбоэмболических и геморрагических осложнений, чаще диагностировались другие сопутствующие сердечно-сосудистые и хронические некардиальные заболевания, чаще выявлялись сниженная фракция выброса левого желудочка, тахисистолия, отсутствие достижения целевого уровня артериального давления при наличии артериальной гипертонии. При наличии ХСН была более высокой, хотя и недостаточной, частота назначения должной кардиоваскулярной фармакотерапии, при этом частота назначения антикоагулянтов была меньше. При ФП на фоне ХСН была выше частота смерти от всех причин, развития нефатальных инфаркта миокарда и мозгового инсульта, частота госпитализаций по поводу сердечно-сосудистой патологии.
фибрилляция предсердийхроническая сердечная недостаточностьамбулаторные и госпитальные регистрысочетанные заболеваниямультиморбидностьфармакотерапияисходысмертностьatrial fibrillationchronic heart failureoutpatient and hospital registriesconcomitant diseasesmultimorbiditypharmacotherapyoutcomesmortalityСтатья опубликована при финансовой поддержке компании Пфайзер. Компания Пфайзер не участвовала в получении данных и написании статьи. Мнение автора может не совпадать с мнением компании. Исследование проведено при поддержке Национального медицинского исследовательского центра терапии и профилактической медицины.The article was published with the financial support of the Pfizer company. Pfizer did not participate in the data ac- quisition and writing of the article. The opinion of the author may not coincide with the opinion of the company. The study was performed with the support of the National Medical Research Center for Therapy and Preventive Medicine.Introduction
Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with an increased risk of stroke, death from stroke, and hospitalization [1]. According to epidemiological studies, about 2% of the population have this disease [2]. At the same time, the AF prevalence increases with age [3][4] and with the appearance of cardiovascular diseases (CVD) in patients [5]. It's very important to study the combination of AF with chronic heart failure (CHF) both in connection with the frequent combination of these conditions (10% of patients with moderate CHF and up to 50% with severe CHF have such a combination), and with the peculiarities of drug treatment when these two pathologies are combined [6][7].
According to the EPOCHA epidemiological study (data for 2017), AF was also diagnosed in 12.3% of patients with CHF [8], and according to the results of the study by E.V. Oshchepkova et al. [9] AF was detected in 5% of patients with CHF at the outpatient stage and in 17% at the hospital stage (and not only in cases of CHF decompensation). Also, according to the EPOCHA-decompensation study, AF was diagnosed in 46.3% of those hospitalized with CHF decompensation [10].
Also, a significant proportion of patients with AF are diagnosed with CHF. In the PROFILE registry, which included outpatients from a specialized cardiology unit, 49.3% of patients with AF had CHF [11], and in the European EORP-AF registry, which included both outpatients and inpatients who consulted cardiologists, 39.5% patients with AF had CHF [12]. It's fundamentally important for the planning and improvement of treatment and prevention care for patients with CVDs is the creation of medical registries in order to assess the compliance of treatment in clinical practice with current recommendations, to determine the frequency of AF and CHF combination with other cardiovascular and chronic noncardiac diseases, as well as to analyze the outcomes with these conditions [13][15].
The study aim to assess in clinical practice the structure of multimorbidity, cardiovascular pharmacotherapy and outcomes in patients with a combination of AF and CHF based on prospective registries of patients with CVD.
Material and methods
Data from 9 registries were analyzed, which included a total of 8696 people with CVD, including 3795 patients with AF in the following five regions of the Russian Federation: Moscow, Ryazan, Kursk, Tula, Yaroslavl. Five of these studies are outpatient prospective studies (observation was carried out for 2-6 years), and 4 are hospital studies, of which prospective observation was carried out in three registries for 2-4 years.
Algorithm for the inclusion of patients with AF in the CVD registers
1) The RECVASA registry (Ryazan) included 530 patients with AF out of 3690 people with CVD permanently residing in Ryazan or the Ryazan region, who applied to 3 polyclinics in Ryazan or Ryazan region for the period March-May 2012, September-October 2012 and January-February 2013, in which the outpatient card indicates the presence of a diagnosis of arterial hypertension (AH), coronary heart disease (CHD), CHF, AF or their combinations.
2) The RECVASA FP-Kursk registry included 502 patients with AF living in the city of Kursk, hospitalized in the Kursk City Clinical Emergency Hospital for the period June 2013-May 2014.
3) The RECVASA FP-Moscow registry included 508 patients with AF living in Moscow, hospitalized at the Federal State Budgetary Institution of National Medical Research Center of Therapy and Preventive Medicine in April 2013-March 2014.
4) The RECVASA FP-Tula registry included 1225 patients with AF living in the city of Tula or in the Tula region, hospitalized in the Tula regional clinical hospital in January-December 2013.
5) The RECVASA FP-Yaroslavl registry included 404 patients with AF living in Yaroslavl, who applied to 2 polyclinics in Yaroslavl for the period January-December 2013.
6) The REGION-PO registry included 141 patients with AF out of 475 people living in the city of Ryazan or the Ryazan region, who for the first time after suffering an acute cerebrovascular accident (ACVA) applied to 3 polyclinics in Ryazan or Ryazan region for the period 2014-2015.
7) The REGION-LD registry included 107 patients with AF out of 511 people living in Ryazan or the Ryazan region who underwent ACVA, who applied to 3 polyclinics in Ryazan or Ryazan region for the period 2012-2013.
8) The REGION-Moscow registry included 268 patients with AF out of 900 people permanently residing in Moscow, hospitalized in one of the vascular centers on the basis of a clinical hospital in Moscow for the period 2012-2017, with an indication of ACVA in the clinical diagnosis of medical history.
9) The REGATA registry included 112 patients with AF out of 481 people living in Ryazan or the Ryazan region who had myocardial infarction (MI), who applied to 3 polyclinics in Ryazan or Ryazan region for the period 2012-2013.
A more detailed description of the design, structure of multimorbidity, cardiovascular pharmacotherapy and outcomes in patients from the above registries was published by us earlier [16][23]. This publication contains information on secondary data.
Criteria for inclusion in the study: indication of the AF diagnosis in the outpatient card or in the clinical diagnosis of medical history; going to a polyclinic or hospitalization in a hospital during the above periods of inclusion in the registries The duration of prospective observation of patients was in registries: RECVASA (Ryazan) – 5.8 [ 3.5; 6.5] years, RECVASA FP-Kursk – 2.2 [ 1.7; 2.7] years, RECVASA FP-Moscow – 2.0 [ 1.8; 2.2] years, RECVASA FP-Yaroslavl – 2.0 [ 1.8; 2.7] years, REGION-PO (Ryazan) – 2.0 [ 1.6; 2.8] years, REGION-LD (Ryazan) – 4.3 [ 3.2; 5.1] years, REGION-Moscow – 2.0 [ 1.3; 3.2] years, REGATA (Ryazan) – 6.1 [ 4.0; 6.6] years. Information about the occurrence of events (death, myocardial infarction, cerebral stroke, hospitalization for CVD) and about the drug therapy carried out at the stage of long-term observation was obtained by telephone contact with the patient or during his visit to the doctor, from medical records and electronic databases. The assessment of the frequency of diagnosing combined CVD and chronic noncardial pathology, the appointment of cardiovascular pharmacotherapy, as well as the outcomes of observation was carried out in patients with AF.
The comparison groups were patients with AF combined with CHF and with AF without CHF according to medical records. Comparison of the multimorbidity structure, forms of AF, cardiovascular pharmacotherapy at the stage of inclusion in the registries was carried out within all 9 of the above registries (in 3016 patients with a combination of AF and CHF in 779 patients with AF without CHF). Comparative assessment of long-term outcomes was carried out within 8 registries (excluding the RECVASA FP-Tula registry) in 2019 patients with a combination of AF and CHF and in 551 patients without CHF. This exception was due to the fact that there was no prospective observation of patients after discharge from the hospital in the RECVASA FP-Tula registry.
Descriptive statistics methods were used for statistical processing of the data. Numerical data are presented as M±SD or Me [ 25%; 75%]. The statistical significance of differences in numerical data was assessed using the Student's test. The statistical significance of categorical data was assessed using the chi-square test. Differences were considered statistically significant at p<0.05. The data were statistically processed using the Statistica 7.0 and Stata 15.0 software.
Results
The 3795 patients with AF included in the study had an average age of 71.7±10.7 years, among them there were 1601 men (42.2%), and 2194 women (57.8%). The combination of AF and CHF was diagnosed in 3016 (79.5%) patients (average age was 72.0±10.3 years, 41.8% of men). The group of patients with AF without CHF consisted of 779 people (average age was 70.3±12.0 years, 43.5% of men). Patients with a combination of AF and CHF patients, compared with patients with AF without CHF, had a higher risk of thromboembolic complications (CHA2DS2-VASc 4.68±1.59 versus 3.10±1.50; p <0.001) and the risk of hemorrhagic complications (HAS-BLED 1.59±0.77 versus 1.33±0.76; p <0.05).
Patients with AF with CHF, compared with patients with AF without CHF, were significantly more likely to be diagnosed with AH, СHD, previous MI, diabetes mellitus, respiratory diseases, chronic kidney disease (CKD) and obesity (Table 1). We note that 87.9% of patients in the group with AF and CHF also had a combination of AH and СHD. The proportions of people with coronary heart disease (by 1.6 times), MI (by 2.0 times), with a combination of hypertension and coronary heart disease (by 1.7 times) differed to the greatest extent between the comparison groups.
Table 1. The proportion of people with concomitant CVDs and chronic noncardiac diseases among patients with AF and with/without CHF (data from the RECVASA, REGION, REGATA registries)*
Persistent forms of arrhythmia were recorded more often among patients with AF in the presence of CHF than in the absence of CHF, and the paroxysmal form was recorded less frequently, while the frequency of indication of newly diagnosed AF in the comparison groups didn't differ significantly (Table 2).
Table 2. Forms of atrial fibrillation in patients with / without CHF (data from the RECVASA, REGION, REGATA registries)*
Determination of the left ventricular ejection fraction in patients with AF was carried out insufficiently often (in 57.2% of cases), while it was significantly more often carried out in AF associated with CHF (in 59.3% of cases) than in AF without CHF (51.0%, p<0.001; Table 3). The proportion of patients with reduced and intermediate ejection fraction (≤40% and 41-49%, respectively) was significantly higher among patients with CHF, which should correspond to the presence of this pathology. But we note that decreased (1.2%) or intermediate (2.8%) values of the left ventricular ejection fraction were detected in a small part of patients with AF despite the absence of a CHF diagnosis. We also point out that tachysystole and the lack of reaching the target blood pressure level in the presence of hypertension, which are risk factors for cardiovascular complications, were recorded in patients with a combination of AF and CHF more often than in the absence of CHF. In addition, almost every fifth patient in both comparison groups also had a prognostically unfavorable decrease in hemoglobin level (in men <130 g/l and in women <120 g/l), in the absence of significant differences between the groups (18.7% and 20.2%; p=0.50).
Table 3. Evaluation of left ventricular ejection fraction, frequency of detection of tachysystole and high blood pressure in patients with AF with or without CHF
Prescribed cardiovascular pharmacotherapy was more consistent with clinical guidelines in patients with a combination of AF and CHF compared with the group of patients with AF without CHF (Table 4). In particular, antihypertensive therapy for hypertension, angiotensin-converting enzyme inhibitors (ACEi)/antiotensin receptor blockers (ARBs) and beta-blockers for previous MI, statins for coronary heart disease, and ACEi for a history of cerebral stroke were more often prescribed. Nevertheless, anticoagulant therapy was less frequently prescribed in the group of patients with a combination of AF and CHF than in AF without CHF (38.8% versus 49.0%; p <0.001), despite the higher risk of thromboembolic complications.
Table 4. The frequency of prescribing prognostically significant pharmacotherapy for CVD in patients with AF with / without CHF (data from the RECVASA, REGION, REGATA registries)
It's necessary to pay attention to the fact that anticoagulants were prescribed in patients with a combination of AF, CHF and CHD only in 35.2% (933 of 2652) cases, and in patients with AF without CHF, but with CHD – in 36.2% (151 out of 417). It's fundamentally important to note that the frequency of unreasonable prescription of antiplatelet agents was 81.0% (1392 out of 1719) among patients with AF in combination with CHF and CHD who didn't receive anticoagulants. The frequency of prescribing antiplatelet agents instead of anticoagulants in patients with AF without CHF but with CHD was 52.3% (139 of 266). In general, the frequency of unreasonable prescription of antiplatelet agents instead of anticoagulants was significantly higher in the group of patients with AF, CHF and CHD – 52.5% (1392 of 2652) than in the group of patients with AF and CHD without CHF – 33.3% (139 of 417; p<0.001).
Table 5 shows data that the following differences in the frequency of prescribing different options for anticoagulant therapy were in patients with AF in combination with CHF, in contrast to patients with AF without CHF: direct oral anticoagulants (DOAC) were prescribed 1.9 times less frequently (30.8% and 58.4% of all cases of prescribing anticoagulants in these groups), warfarin was prescribed 1.7 times more often (61.7% and 36.1%, respectively), other anticoagulants were prescribed 1.1 times more often (7.4%, compared to 5.5%).
Table 5. The frequency of prescribing anticoagulants to patients with AF in the presence / absence of a combination with CHF (data from the RECVASA, REGION, REGATA registries)
According to prospective observation, the proportion of deaths from all causes, the incidence of non-fatal myocardial infarction, as well as hospitalizations for CVD were significantly higher in patients with AF combined with CHF, compared with patients with AF without CHF (Table 6).
Table 6. Frequency of fatal and non-fatal events according to the data of prospective observation of patients with AF in the presence / absence of a combination with CHF
According to the results of this study, most patients (79.5%) with AF had CHF, which is significantly more than according to several foreign studies (for example, 39.5% and 47.5% of patients with AF had CHF according to the results of the studies EORPAF [12] and EORP-AF pilot [24], and according to the Framingham study, CHF developed in one third of patients with AF [25]). The higher percentage of patients with CHF among patients with AF in our work may be due to the fact that the number of patients with preserved left ventricular ejection fraction depends on the diagnostic criteria used, while the proportion of patients with a diagnosis of CHF is greater in clinical diagnosis without using additional echocardiographic parameters and determining the natriuretic peptide level (NTproBNP) [26]. This is also due to the fact that patients with cerebral stroke were included in some of the registries we analyzed, and the presence of CHF is one of the risk factors for stroke in patients with AF [1].
The work shows that patients with AF in combination with CHF were characterized by a large number of concomitant cardiovascular and chronic noncardiac diseases, in particular, hypertension, coronary heart disease, previous myocardial infarction, diabetes mellitus, respiratory diseases, chronic kidney disease and obesity compared with patients with CHF without AF. The EORP-AF pilot registry also showed that the proportion of cases of coronary heart disease, heart defects, COPD, diabetes mellitus, previous strokes, chronic kidney disease is higher among patients with CHF and AF compared to patients with AF without CHF [24].
More pronounced multimorbidity in patients with AF in combination with CHF is due to the fact that CHF can be caused by a number of other reasons besides AF, in particular hypertension, coronary heart disease, diabetes mellitus and other reasons [27]. Also, patients with a combination of CHF and AF were older (on average by 1.7 years), and the likelihood of CHF, AF, and other diseases increases with age [3].
According to this study, the persistent form of this arrhythmia, corresponding to the later stages of its continuum, was recorded in patients with AF and CHF more often than in the absence of CHF. This result is also consistent with the EORP-AF pilot data [24]. Perhaps this is due to the longer existence of AF and a more pronounced change in the morphofunctional parameters of the atria. The clinical features of patients with paroxysmal and permanent AF differ significantly, which may affect treatment and prognosis. The Realise AF registry showed that the incidence of cardiovascular and noncardiac diseases (CHF, CHD, chronic obstructive pulmonary disease, cerebrovascular diseases and thromboembolic complications) increased as AF progressed from paroxysmal to permanent form [28]. This question will be the subject of our further studies and subsequent publications.
An important result we obtained is the fact that the prescribed cardiovascular pharmacotherapy was more consistent with clinical guidelines in patients with a combination of AF and CHF, compared with the group of patients with AF without CHF. In particular, antihypertensive therapy for hypertension, ACEi/ARBs and beta-blockers for previous myocardial infarction, statins for coronary heart disease, and ACEi with a history of cerebral stroke were more often prescribed. The frequency of prescribing beta-blockers to patients with AF and CHF was 60.8%, which is lower than in patients with AF and CHF in the European EORP-AF pilot registry (76.4%) [24]. In general, according to the EORP-AF pilot registry, patients with a combination of CHF and AF were also more often prescribed basic drugs for the treatment of cardiovascular diseases [24] than patients with AF without CHF.
However, we note that anticoagulant therapy was prescribed in the group of patients with a combination of AF and CHF less often than in the group of patients with AF without CHF, despite the higher risk of thromboembolic complications. This was partly due to the fact that in some cases the attending physicians unreasonably gave preference to antiplatelet agents in the presence of coronary heart disease, and anticoagulants were not prescribed. An interesting finding of the work is the fact that patients with CHF were prescribed direct oral anticoagulants 1.9 times less often and warfarin was prescribed 1.4 times more often than in the absence of CHF. This is difficult to explain, since direct oral anticoagulants are the preferred drugs in patients with a combination of AF and CHF, with the exception of patients with moderate to severe mitral stenosis, mechanical valves, and a number of rare causes of CHF (eg, noncompact cardiomyopathy) [29, 30].
A low percentage of prescribing anticoagulants in patients with AF (both with CHF and without CHF) has also been shown in several Russian and foreign studies [31][32]. Active work with doctors is required to address this issue to reduce the incidence of strokes in patients with AF.
Analysis of long-term outcomes revealed that patients with a combination of AF and CHF, compared with patients with AF without CHF, had higher mortality from all causes, the incidence of non-fatal myocardial infarction and cerebral stroke, and the proportion of hospitalizations for CVD was higher. A number of other studies have also shown that the presence of CHF worsens the prognosis of patients with AF [25][32], and the frequency of hospitalizations is most likely associated with more frequent decompensations of CHF and AF and the need for inpatient treatment in patients with comorbid diseases.
Conclusion
Patients with a combination of AF and CHF, compared with the group of patients with AF without CHF, were older, had a higher risk of thromboembolic and hemorrhagic complications, they were more often diagnosed with other concomitant cardiovascular and chronic noncardiac diseases, as well as decreased left ventricular ejection fraction, tachysystole and the lack of reaching the target level of blood pressure in the presence of arterial hypertension was more often detected. The frequency of prescribing proper cardiovascular pharmacotherapy was higher, albeit insufficient, in the presence of CHF, while the frequency of prescribing anticoagulants was less. The incidence of death from all causes and the development of non-fatal myocardial infarction and cerebral stroke, as well as the incidence of hospitalizations for cardiovascular pathology, were higher in AF associated with CHF.
Relationships and activities: The article was published with the financial support of the Pfizer company. Pfizer did not participate in the data acquisition and writing of the article. The opinion of the author may not coincide with the opinion of the company.Funding. The study was performed with the support of the National Medical Research Center for Therapy and Preventive Medicine.
ReferencesHindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-7. DOI:10.1016/j.amjcard.2013.05.063.Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-7. DOI:10.1016/j.amjcard.2013.05.063.Heeringa J, Van Der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006;27(8):949-53. DOI:10.1093/eurheartj/ehi825.Heeringa J, Van Der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006;27(8):949-53. DOI:10.1093/eurheartj/ehi825.Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Am Med Assoc. 2001;285(18):2370-5. DOI:10.1001/jama.285.18.2370.Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Am Med Assoc. 2001;285(18):2370-5. DOI:10.1001/jama.285.18.2370.Allan V, Honarbakhsh S, Casas JP, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?: A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837-50. DOI:10.1160/TH16-11-0825.Allan V, Honarbakhsh S, Casas JP, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?: A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837-50. DOI:10.1160/TH16-11-0825.Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516-25. DOI:10.1161/CIRCULATIONAHA.108.821306.Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516-25. DOI:10.1161/CIRCULATIONAHA.108.821306.Mareev Y, Cleland JGF. Should β-Blockers Be Used in Patients with Heart Failure and Atrial Fibrillation? Clin Ther. 2015;37(10):2215-24. DOI:10.1016/j.clinthera.2015.08.017.Mareev Y, Cleland JGF. Should β-Blockers Be Used in Patients with Heart Failure and Atrial Fibrillation? Clin Ther. 2015;37(10):2215-24. DOI:10.1016/j.clinthera.2015.08.017.Поляков Д.С., Фомин И.В., Беленков Ю.Н., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14. DOI:10.18087/cardio.2021.4.n1628.Polyakov DS, Fomin I V, Belenkov YN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. DOI:10.18087/cardio.2021.4.n1628.Ощепкова Е.В., Лазарева Н.В., Сатлыкова Д.Ф., Терещенко С.Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология. 2015;(5):22-8.Oshchepkova EV, Lazareva NV, Satlykova DF, Tereshchenko SN. [The First Results of the Russian Register of Chronic Heart Failure. Kardiologiia. 2015;55(5):22-8.Поляков Д.С., Фомин И.В., Валикулова Ф.Ю., и др. Эпидемиологическая программа ЭПОХА-ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА-Д-ХСН). Сердечная Недостаточность. 2016;17(5):299-305. DOI:10.18087/RHFJ.2016.5.2239.Polyakov DS, Fomin IV, Valikulova FY, et al. The EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D-CHF). Russ Hear Fail J. 2016;17(6):299-305. DOI:10.18087/RHFJ.2016.5.2239.Лукина Ю.В., Кутишенко Н.П., Толпыгина С.Н., и др. Основные факторы приверженности к приему новых оральных антикоагулянтов и ее динамика у пациентов с неклапанной фибрилляцией предсердий в рамках амбулаторного регистра: результаты исследования АНТЕЙ. Кардиоваскулярная Терапия и Профилактика. 2020;19(5):2680. DOI:10.15829/1728-8800-2020-2680.Lukina YV, Kutishenko NP, Tolpygina SN, et al. Main factors of adherence to new oral anticoagulants and its dynamics in outpatients with nonvalvular atrial fibrillation: Results of the antey study. Cardiovasc Ther Prev. 2020;19(5):2680. DOI:10.15829/1728-8800-2020-2680.Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747-57. DOI:10.1093/EUROPACE/EUX301.Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747-57. DOI:10.1093/EUROPACE/EUX301.Беленков Ю.Н., Арутюнов Г.П., Барбараш О.Л., и др. Значение и ценность сравнительных исследований «реальной клинической практики» в современной кардиологии. Заключение совета экспертов от 18.12.2020. Кардиология. 2021;61(5):79-81. DOI:10.18087/CARDIO.2021.5.N1646.Belenkov Y, Arutunov G, Barbarash O, et al. Value of comparative studies of “real clinical practice” in modern cardiology. Position paper based on the expert council discussion dated 12/18/2020. Kardiologiia. 2021;61(5):79-81. DOI:10.18087/CARDIO.2021.5.N1646.Cohen AT, Goto S, Schreiber K, Torp-Pedersen C. Why do we need observational studies of everyday patients in the real-life setting? Eur Hear J Suppl. 2015;17(suppl_D):D2-D8. DOI:10.1093/EUR-HEARTJ/SUV035.Cohen AT, Goto S, Schreiber K, Torp-Pedersen C. Why do we need observational studies of everyday patients in the real-life setting? Eur Hear J Suppl. 2015;17(suppl_D):D2-D8. DOI:10.1093/EUR-HEARTJ/SUV035.Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В., и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная терапия и профилактика. 2021;20(2):2786. DOI:10.15829/1728-8800-2021-2786.Martsevich SY, Kutishenko NP, Lukina Y V, et al. Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovasc Ther Prev. 2021;20(2):61-6. DOI:10.15829/1728-8800-2021-2786.Лукьянов М.М., Бойцов С.А., Якушин C.C., и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2014;10(4):366-77. DOI:10.20996/1819-6446-2014-10-4-366-377.Loukianov MM, Boytsov SA, Yakushin SS, et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of" atrial fibrillation" in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014;10(4):366-77. DOI:10.20996/1819-6446-2014-10-4-366-377.Лукьянов М.М., Марцевич С.Ю., Драпкина О.М., и др. Терапия оральными антикоагулянтами у больных с фибрилляцией предсердий в амбулаторной и госпитальной медицинской практике (данные регистров РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2019;15(4):538-45. DOI:10.20996/1819-6446-2019-15-4-538-545.Loukianov MM, Martsevich SY, Drapkina OM, et al. The therapy with oral anticoagulants in patients with atrial fibrillation in outpatient and hospital settings (data from RECVASA registries). Ration Pharmacother Cardiol. 2019;15(4):538-45. DOI:10.20996/1819-6446-2019-15-4-538-545.Марцевич С.Ю., Кутишенко Н.П., Лукьянов М.М., и др. Госпитальный регистр больных, перенесших острое нарушение мозгового кровообращения (РЕГИОН): портрет заболевшего и исходы стационарного этапа лечения. Кардиоваскулярная Терапия и Профилактика. 2018;17(6):32-8. DOI:10.15829/1728-8800-2018-6-32-38.Martsevich SY, Kutishenko NP, Lukyanov MM, et al. Hospital register of patients with acute cerebrovascular accident (REGION): Characteristics of patient and outcomes of hospital treatment. Cardiovasc Ther Prev. 2018;17(6):32-8. DOI:10.15829/1728-8800-2018-6-32-38.Переверзева К.Г., Якушин С.С., Грачева А.И., и др. Пациент с инфарктом миокарда в анамнезе: сравнение тактики ведения терапевтом и кардиологом по данным регистра РЕГАТА (РЕГистр пациентов, перенесших инфАркТ миокардА). Кардиоваскулярная Терапия и Профилактика. 2020;19(3):2525. DOI:10.15829/1728-8800-2020-2525.Pereverzeva KG, Yakushin SS, Gracheva AI, et al. Post-myocardial infarction patients: A comparison of management by a physician and a cardiologist according to the REGATA register. Cardiovasc Ther Prev. 2020;19(3):2525. DOI:10.15829/1728-8800-2020-2525.Лукьянов М.М., Якушин С.С., Марцевич С.Ю., и др. Сердечно-сосудистые заболевания и их медикаментозное лечение у больных, перенесших острое нарушение мозгового кровообращения: данные амбулаторного регистра РЕГИОН. Рациональная Фармакотерапия в Кардиологии. 2018;14(6):879-86. DOI:10.20996/1819-6446-2018-14-6-870-878.Loukianov MM, Yakushin SS, Martsevich SY, et al. Cardiovascular diseases and drug treatment in patients with the history of cerebral stroke: Data of the outpatient registry region. Rational Pharmacotherapy in Cardiology. 2018;14(6):879-86. DOI:10.20996/1819-6446-2018-14-6-870-878.Валиахметов М.Н., Гомова Т.А., Лукьянов М.М., и др. Больные с фибрилляцией предсердий в условиях многопрофильного стационара: структура госпитализации, сочетанные сердечно-сосудистые заболевания и медикаментозная терапия (данные регистра РЕК-ВАЗА ФП-Тула). Рациональная Фармакотерапия в Кардиологии. 2017;13(4):484-94. DOI:10.20996/1819-6446-2017-13-4-495-505.Valiakhmetov MN, Gomova TA, Loukianov MM, et al. Patients with atrial fibrillation in multidisciplinary hospital: Structure of hospitalization, concomitant cardiovascular diseases and drug treatment (data of RECVASA AF-Tula registry). Rational Pharmacotherapy in Cardiology. 2017;13(4):495-505. DOI:10.20996/1819-6446-2017-13-4-495-505.Михин В.П., Масленникова Ю.В., Лукьянов М.М., и др. Медикаментозная терапия больных ишемической болезнью сердца в сочетании с фибрилляцией предсердий в реальной медицинской практике (результаты регистра РЕКВАЗА ФП-Курск). Курский Научно-практический Вестник «Человек и Его Здоровье». 2017;0(2):49-54. DOI:10.21626/vestnik/2017-2/09.Mikhin VP, Maslennikova YV, Lukyanov MM, et al. Drug therapy in patients with coronary heart disease in combination with atrial fibrillation in real medical practice (results of RECVASA AF-Kursk registry). Kursk Scientific and Practical Bulletin "Man and His Health". 2017;(2):49-54. DOI:10.21626/vestnik/2017-2/09.Якусевич В.В., Позднякова Е.М., Якусевич В.Вл. и др. Амбулаторный пациент с фибрилляцией предсердий: основные характеристики. Первые данные регистра РЕКВАЗА ФП-Ярославль. Рациональная фармакотерапия в кардиологии 2015;11(2):149-52. DOI:10.20996/1819-6446-2015-11-2-149-152.Yakusevich VV, Pozdnyakova EM, Yakusevich VV, et al. An outpatient with atrial fibrillation: key features. The first data of REKVAZA FP-YAROSLAVL register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149-52. DOI:10.20996/1819-6446-2015-11-2-149-152.Lip GYH, Laroche C, Popescu MI, et al. Heart failure in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. 2015;17(6):570-82. DOI:10.1002/ejhf.254.Lip GYH, Laroche C, Popescu MI, et al. Heart failure in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. 2015;17(6):570-82. DOI:10.1002/ejhf.254.Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484-92. DOI:10.1161/CIRCULATIONAHA.115.018614.Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484-92. DOI:10.1161/CIRCULATIONAHA.115.018614.Мареев Ю. В., Гарганеева А.А., Тукиш О.В. и др. Сложности в диагностике сердечной недостаточности с сохраненной фракцией выброса в реальной клинической практике: диссонанс между клиникой, эхокардиографическими изменениями, величиной натрийуретических пептидов и шкалой H2FPEF. Кардиология. 2019;59(12S):37-45. DOI:10.18087/cardio.n695.Mareev Y V, Garganeeva AA, Tukish OV, et al. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2019;59(12S):37-45. DOI:10.18087/cardio.n695.Поляков ДC, Фомин ИВ, Беленков ЮН, и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14. DOI:10.18087/cardio.2021.4.n1628.Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. DOI:10.18087/cardio.2021.4.n1628.Chiang CE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632-9. DOI:10.1161/CIRCEP.112.970749.Chiang CE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632-9. DOI:10.1161/CIRCEP.112.970749.Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2020;25(11):311-74. DOI:DOI:10.15829/1560-4071-2020-4083.Tereshchenko SN, Galyavich AS, Uskach TM, et al. 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol. 2020;25(11):4083. DOI:DOI:10.15829/1560-4071-2020-4083.McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI:10.1093/eurheartj/ehab368.McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI:10.1093/eurheartj/ehab368.Терещенко С.Н., Жиров И.В., Романова Н.В., и др. Первый российский регистр больных хронической сердечной недостаточностью и фибрилляцией предсердий (РИФ-ХСН): дизайн исследования. Рациональная Фармакотерапия в Кардиологии. 2015;11(6):577-81. DOI:10.20996/1819-6446-2015-11-6-577-581)Tereshchenko SN, Zhirov IV, Romanova NV, et al The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): Study design. Rational Pharmacotherapy in Cardiology. 2015;11(6):577-81. DOI:10.20996/1819-6446-2015-11-6-577-581)Cottin Y, Maalem Ben Messaoud B, Monin A, et al. Temporal relationship between atrial fibrillation and heart failure development analysis from a nationwide database. J Clin Med. 2021;10(21):5101. DOI:10.3390/jcm10215101.Cottin Y, Maalem Ben Messaoud B, Monin A, et al. Temporal relationship between atrial fibrillation and heart failure development analysis from a nationwide database. J Clin Med. 2021;10(21):5101. DOI:10.3390/jcm10215101.
The authors declare that there are no conflicts of interest present.